The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities

被引:37
作者
Kaus, LC
Gillespie, WR
Hussain, AS
Amidon, GL
机构
[1] GloboMax LLC, Hanover, MD 21076 USA
[2] US FDA, CDER, OTR, Rockville, MD 20857 USA
[3] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
关键词
biopharmaceutic classification system; peak concentration; permeability;
D O I
10.1023/A:1018836727001
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To theoretically investigate the impact of gastric emptying half-time, intestinal transit time and the time for 85% in vivo dissolution on the peak concentration and area-under-the curve of model drugs. Methods. Simulations were performed using mathematical models of gastrointestinal physiology and pharmacokinetics of model drugs with different,gastrointestinal permeability. They were used to investigate the effect of different permutations of gastric emptying times, intestinal transit times, dissolution rates and effective permeabilities on the maximum plasma drug concentration and the area-under-the-curve of immediate release tablets relative to an oral solution (i.e,, Cmax(tablet)/ Cmax(solution) and AUC(tablet)/AUC(solution)). Results. The higher the permeability of the drug, the more sensitive the Cmax ratio is to dissolution rate and gastric emptying rate. As the intestinal transit time becomes more rapid, the sensitivity to T85% dissolution time and gastric emptying half-time increases. There is less dependence for the AUC ratio on the gastric emptying time and dissolution rate. Conclusions. Under the assumptions of the models, the criterion of 85% dissolution in 15 minutes (T85%) for classifying a rapidly dissolving drug product is relatively conservative since the Cmax ratio exceeded 0.8 for a T85% dissolution time of one hour and a gastric emptying half-time faster than 0.2 hour over a wide range of permeabilities.
引用
收藏
页码:272 / 280
页数:9
相关论文
共 14 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]   TRANSIT OF PHARMACEUTICAL DOSAGE FORMS THROUGH THE SMALL-INTESTINE [J].
DAVIS, SS ;
HARDY, JG ;
FARA, JW .
GUT, 1986, 27 (08) :886-892
[3]   PHYSICOCHEMICAL MODEL FOR DOSE-DEPENDENT DRUG ABSORPTION [J].
DRESSMAN, JB ;
FLEISHER, D ;
AMIDON, GL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (09) :1274-1279
[4]   EFFECT OF SODIUM ACID PYROPHOSPHATE ON RANITIDINE BIOAVAILABILITY AND GASTROINTESTINAL TRANSIT-TIME [J].
KOCH, KM ;
PARR, AF ;
TOMLINSON, JJ ;
SANDEFER, EP ;
DIGENIS, GA ;
DONN, KH ;
POWELL, JR .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1027-1030
[5]   REGIONAL JEJUNAL PERFUSION, A NEW INVIVO APPROACH TO STUDY ORAL-DRUG ABSORPTION IN MAN [J].
LENNERNAS, H ;
AHRENSTEDT, O ;
HALLGREN, R ;
KNUTSON, L ;
RYDE, M ;
PAALZOW, LK .
PHARMACEUTICAL RESEARCH, 1992, 9 (10) :1243-1251
[6]  
Levet-Trafit B., 1996, Life Sciences, V58, P359
[7]   THE INFLUENCE OF VARIABLE GASTRIC-EMPTYING AND INTESTINAL TRANSIT RATES ON THE PLASMA-LEVEL CURVE OF CIMETIDINE - AN EXPLANATION FOR THE DOUBLE PEAK PHENOMENON [J].
OBERLE, RL ;
AMIDON, GL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (05) :529-544
[8]   PREDICTING FRACTION DOSE ABSORBED IN HUMANS USING A MACROSCOPIC MASS BALANCE APPROACH [J].
SINKO, PJ ;
LEESMAN, GD ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1991, 8 (08) :979-988
[9]   COMPARISON OF INTESTINAL PERMEABILITIES DETERMINED IN MULTIPLE IN-VITRO AND IN-SITU MODELS - RELATIONSHIP TO ABSORPTION IN HUMANS [J].
STEWART, BH ;
CHAN, OH ;
LU, RH ;
REYNER, EL ;
SCHMID, HL ;
HAMILTON, HW ;
STEINBAUGH, BA ;
TAYLOR, MD .
PHARMACEUTICAL RESEARCH, 1995, 12 (05) :693-699
[10]   USE OF A PHARMACOKINETIC MODEL INCORPORATING DISCONTINUOUS GASTROINTESTINAL ABSORPTION TO EXAMINE THE OCCURRENCE OF DOUBLE PEAKS IN ORAL CONCENTRATION-TIME PROFILES [J].
SUTTLE, AB ;
POLLACK, GM ;
BROUWER, KLR .
PHARMACEUTICAL RESEARCH, 1992, 9 (03) :350-356